English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, October 24, 2024
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Tuesday, October 22, 2024
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Thursday, October 17, 2024
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Tuesday, October 15, 2024
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Wednesday, October 9, 2024
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Tuesday, October 8, 2024
Lexaria Updates Current GLP-1 Market
Tuesday, October 1, 2024
Lexaria Appoints Michael Shankman as Chief Financial Officer
Friday, September 27, 2024
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Thursday, September 5, 2024
Lexaria Releases Strategic Letter from the Outgoing CEO
Lexaria Welcomes Industry Veteran as New CEO

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575